This book explores the intersection between epigenetic biomarkers and clinical diagnostics, and is divided into three distinct sections, including the basis of epigenetic mechanisms, the importance of the sample quality, and the technologies and methods used to discover and analyze epigenetic biomarkers.
Preface José Luis García-Giménez
1. Epigenetic Biomarkers: New findings, perspectives, and
future directions in diagnostics José Luis García-Giménez,
Toshikazu Ushijima, and Trygve O. Tollefsbol
2. The importance of Biobanks in epigenetic studies Lorena
Peiró-Chova, Olga Bahamonde Ponce, Carolina Abril-Tormo, Jacobo
Martínez-Santamaría, José Antonio López-Guerrero and Peter H.J.
Riegman
3. Epigenetic Mechanisms as Key Regulators in Disease. Clinical
Implications Abdelhalim Boukaba, José Luis García-Giménez
4. The evolution of new technologies and methods in clinical
epigenetics research Tandy L. Dolin Petrov and Nicole C. Riddle
5. Biomarkers and methodologies for monitoring epigenetic drug
effects in cancer Marianne B. Treppendahl, Lasse Sommer Kristensen
and Kirsten Grønbæk
6. Genome-wide techniques for the study of clinical epigenetic
biomarkers Eneda Toska and F Javier Carmona Sanz
7. Sequenom MassARRAY technology for the analysis of DNA
methylation. Clinical applications Enrique J. Buso and Marisa
Iborra
8. The role of Methylation-specific PCR and associated techniques
in clinical diagnostics Fang Zhao and Bharati Bapat
9. Pyrosequencing and its application in epigenetic clinical
diagnostics Ana-Maria Florea
10. Mass spectrometry for the identification of post-translational
modifications in histones and its application in clinical
epigenetics Roberta Noberini, Alessandro Cuomo and Tiziana
Bonaldi
11. High-throughput analysis of non-coding RNAs: implications in
clinical epigenetics Valerio Costa, Maria R Matarazzo, Miriam
Gagliardi, Roberta Esposito, Alfredo Ciccodicola
12. Circulating non-coding RNAs as clinical biomarkers Francesco
Russo, Flavia Scoyni, Alessandro Fatica, Marco Pellegrini, Alfredo
Ferro, Alfredo Pulvirenti and Rosalba Giugno
13. DNA methylation biomarkers in lung cancer Juan Sandoval and
Paula Lopez Serra
14. DNA methylation alterations as biomarkers for Prostate Cancer
João Ramalho-Carvalho, Rui Henrique, Carmen Jerónimo
15. DNA methylation in breast cancer Raimundo Cervera, Alberto
Ramos, Ana Lluch and Joan Climent
16. DNA methylation in obesity and associated diseases Ana B
Crujeiras and Angel Díaz-Lagares
17. DNA Methylation Biomarkers in Asthma and Allergy Avery DeVries
and Donata Vercelli
18. DNA Methylation in Pregnancy Complications Deepali Sundrani,
Vinita Khot and Sadhana Joshi
19. Epigenetics in Infectious Diseases Genevieve Syn, Jenefer M.
Blackwell and Sarra E. Jamieson
20. DNA Methylation in Neurodegenerative Diseases Sahar Al-Mahdawi,
Sara Anjomani Virmouni and Mark A. Pook
21. The histone code and disease: post-translational modifications
as potential prognostic factors for clinical diagnosis Nicolas G.
Simonet, George Rasti and Alejandro Vaquero
22. Histone Post-Translational Modifications and Chromatin
Remodelers in Prostate Cancer Filipa Quintela Vieira, Diogo
Almeida-Rios, Inês Graça, Rui Henrique and Carmen Jerónimo
23. Histone post-translational modifications in breast cancer and
their use in clinical diagnosis and prognosis Luca Magnani, Annita
Louloupi and Wilbert Zwart
24. Histone variants and post-translational modifications in
spermatogenesis and infertility Juan Ausio, Yinan Zhang and
Toyotaka Ishibashi
25. Circulating histones and nucleosomes as biomarkers in sepsis
and septic shock José Luis García Giménez, Carlos Romá Mateo, Marta
Seco Cervera, José Santiago Ibañez Cabellos and Federico V.
Pallardó
26. Chromatin landscape and epigenetic signatures in neurological
disorders: emerging perspectives for biological and clinical
research Pamela Milani and Ernest Fraenkel
27. MicroRNAs deregulation in lung cancer and their use as clinical
tools Paula Lopez-Serra and Juan Sandoval
28. Circulating Nucleic Acids as Prostate Cancer Biomarkers Claire
E. Fletcher, Ailsa Sita-Lumsden, Akifumi Shibakawa and Charlotte L.
Bevan
29. microRNAs in breast cancer and their value as biomarkers Olafur
Andri Stefansson
30. microRNAs in bone and soft tissue sarcomas and their value as
biomarkers Tomohiro Fujiwara, Yu Fujita, Yutaka Nezu, Akira Kawai,
Toshifumi Ozaki, Takahiro Ochiya
31. miRNAs in the pathophysiology of diabetes and their value as
biomarkers Eoin Brennan, Aaron McClelland, Shinji Hagiwara,
Catherine Godson and Phillip Kantharidis
Dr. Garcia-Gimenez is a Senior Researcher at the Consortium Center for Biomedical Network Research, the Spanish Institute of Health Carlos III (ISCIII), and the INCLIVA Biomedical Research Institute, in the Dept. of Physiology at the Medicine and Dentistry School at the University of Valencia, Spain. Dr. García-Giménez is founder and CEO of EpiDisease S.L. (Spin-Off of CIBER-ISCIII), which develops the technology based on the patent EP15382319.0, currently in national phases (USTPO, EPO, CIPO and SIPO). EpiDisease received NEOTEC funds from CDTI and the Seal of Excellence from the European Commission in the SME Instrument Phase II H2020. Dr. García-Giménez has received 7 scientific and entrepreneurship national and international awards, including the National Award for Young Entrepreneurs in 2013 (awarded by the Spanish Ministry of Health) and the European Young Researcher from the Free Radical Research Society in 2009 and more recently the Eureka Innovation and Entrepreneurship Award in Melbourne (Australia). Dr. Garcia-Gimenez is a researcher at the University of Valencia. He is early in his career, but has been noticed as an up-and-coming authority in epigenetic biomarker research as it relates to disease, stress, and exercise.
Ask a Question About this Product More... |